Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Clinical trial NCT07037459 · RECRUITING

Trial details

NCT number: NCT07037459
Sponsor: Amgen
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Heart Failure With Preserved Ejection Fraction Heart Failure With Mildly Reduced Ejection Fraction Obesity

Start date: 2025-06-25
Primary completion: 2028-06-30
Enrollment: 5056

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.